Literature DB >> 32172233

Major Predictive Factors for Progression of Early to Late Age-Related Macular Degeneration.

Vasilena Sitnilska1, Eveline Kersten2, Lebriz Altay3, Tina Schick1, Philip Enders1, Eiko K de Jong2, Thomas Langmann4, Carel B Hoyng2, Anneke I den Hollander2,5, Sascha Fauser1,6.   

Abstract

INTRODUCTION: We present a prediction model for progression from early/intermediate to advanced age-related macular degeneration (AMD) within 5.9 years.
OBJECTIVES: To evaluate the combined role of genetic, nongenetic, and phenotypic risk factors for conversion from early to late AMD over ≥5 years.
METHODS: Baseline phenotypic characteristics were evaluated based on color fundus photography, spectral-domain optical coherence tomography, and infrared images. Genotyping for 36 single-nucleotide polymorphisms as well as systemic lipid and complement measurements were performed. Multivariable backward logistic regression resulted in a final prediction model. RESULTS AND
CONCLUSIONS: During a mean of 5.9 years of follow-up, 22.4% (n = 52) of the patients (n = 232) showed progression to late AMD. The multivariable prediction model included age, CFH variant rs1061170, pigment abnormalities, drusenoid pigment epithelial detachment (DPED), and hyperreflective foci (HRF). The model showed an area under the curve of 0.969 (95% confidence interval 0.948-0.990) and adequate calibration (Hosmer-Lemeshow test, p = 0.797). In addition to advanced age and carrying a CFH variant, pigment abnormalities, DPED, and HRF are relevant imaging biomarkers for conversion to late AMD. In clinical routine, an intensified monitoring of patients with a high-risk phenotypic profile may be suitable for the early detection of conversion to late AMD.
© 2020 S. Karger AG, Basel.

Entities:  

Keywords:  Age-related macular degeneration; Drusenoid pigment epithelial detachment; Genetic factors; Hyperreflective foci; Progression; Risk factors

Year:  2020        PMID: 32172233     DOI: 10.1159/000507196

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  7 in total

1.  Long-term outcomes of drusenoid pigment epithelium detachment in intermediate AMD treated with 577 nm subthreshold micropulse laser: a preliminary clinical study.

Authors:  Zhen Huang; Kai-Yu Deng; Yu-Meng Deng; Yan-Nian Hui; Yan-Ping Song
Journal:  Int J Ophthalmol       Date:  2022-03-18       Impact factor: 1.779

2.  Basic-science observations explain how outer retinal hyperreflective foci predict drusen regression and geographic atrophy in age-related macular degeneration.

Authors:  Qitao Zhang; Jason M L Miller
Journal:  Eye (Lond)       Date:  2021-08-20       Impact factor: 4.456

Review 3.  The Relevance of Oxidative Stress in the Pathogenesis and Therapy of Retinal Dystrophies.

Authors:  Elena B Domènech; Gemma Marfany
Journal:  Antioxidants (Basel)       Date:  2020-04-23

4.  Genetic and environmental risk factors for reticular pseudodrusen in the EUGENDA study.

Authors:  Lebriz Altay; Sandra Liakopoulos; Aileen Berghold; Kerstin-Daniela Rosenberger; Angela Ernst; Anita de Breuk; Anneke I den Hollander; Sascha Fauser; Tina Schick
Journal:  Mol Vis       Date:  2021-12-31       Impact factor: 2.367

5.  Phenotypic Expression of CFH Rare Variants in Age-Related Macular Degeneration Patients in the Coimbra Eye Study.

Authors:  Cláudia Farinha; Patrícia Barreto; Rita Coimbra; Adela Iutis; Maria Luz Cachulo; José Cunha-Vaz; Yara T E Lechanteur; Carel B Hoyng; Rufino Silva
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-08-02       Impact factor: 4.925

6.  Association of imaging biomarkers and local activation of complement in aqueous humor of patients with early forms of age-related macular degeneration.

Authors:  Sascha Fauser; Lebriz Altay; Vasilena Sitnilska; Philip Enders; Claus Cursiefen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-09-02       Impact factor: 3.117

Review 7.  Significance of Hyperreflective Foci as an Optical Coherence Tomography Biomarker in Retinal Diseases: Characterization and Clinical Implications.

Authors:  Serena Fragiotta; Solmaz Abdolrahimzadeh; Rosa Dolz-Marco; Yoichi Sakurada; Orly Gal-Or; Gianluca Scuderi
Journal:  J Ophthalmol       Date:  2021-12-17       Impact factor: 1.909

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.